HUMAN GENE THERAPY RESEARCH IN has a total of 12 patent applications. Its first patent ever was published in 1995. It filed its patents most often in United States, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and telecommunications are VYCELLIX INC, NABEL GARY J and TAKEDA VACCINES INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | United States | 4 | |
#2 | WIPO (World Intellectual Property Organization) | 4 | |
#3 | Australia | 2 | |
#4 | EPO (European Patent Office) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Telecommunications | |
#4 | Foods and drinks |
# | Technology | |
---|---|---|
#1 | Medical preparations | |
#2 | Therapeutic chemical compounds | |
#3 | Microorganisms | |
#4 | Peptides | |
#5 | Transmission | |
#6 | Enzymes |
# | Name | Total Patents |
---|---|---|
#1 | Link Charles J Jr | 8 |
#2 | Link Jr Charles J | 4 |
#3 | Radosevich Thomas J | 3 |
#4 | Mandell Robert B | 3 |
#5 | Wang Suming | 2 |
#6 | Greer Sheldon B | 2 |
#7 | Panchal Rekha G | 1 |
#8 | Levy John P | 1 |
Publication | Filing date | Title |
---|---|---|
AU2114899A | Nucleotide expression systems with reduced immunogenicity for use in gene therapy | |
EP0973902A1 | Radioisotope concentrator methods and compositions | |
US5869035A | Methods and compositions for inducing complement destruction of tissue | |
WO9626743A1 | Radiation enhanced gene therapy for treatment of tumors | |
US5843459A | Differential inactivation of nucleic acids by chemical modification | |
US5830727A | Herpes simplex virus amplicon mini-vector gene transfer system |